A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session1aih1j6nmv9ihie1uni0sroqe2ioo5as): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

Emerging biological agents for hepatitis C. | LitMetric

Emerging biological agents for hepatitis C.

Expert Opin Emerg Drugs

a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.

Published: June 2016

Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic HCV infection. Despite current treatments are well tolerated with a high rate of sustained virological response (SVR), some medical needs remain. Nowadays there are a large number of approved medications for the treatment of HCV infection; nevertheless, new studies are conducted to find new agents and new combinations.

Areas Covered: A literature research of new antiviral compounds indicated for the treatment of HCV infection was achieved by an online search of medication undergoing development on Pubmed and clinicalTrials.gov clinical trials registry. We considered phase I/II studies and some randomized Phase III trials.

Expert Opinion: More knowledge about impact of HCV eradication on disease progression and more confidence regarding drug-drug interaction are needed. Furthermore, each treatment should be individualized targeting the patients needs with the aim not only to obtain viral suppression but also to stop progression of liver disease and HCV related conditions, and to improve patient health status.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2016.1184645DOI Listing

Publication Analysis

Top Keywords

hcv infection
12
treatment hcv
8
hcv
5
emerging biological
4
biological agents
4
agents hepatitis
4
hepatitis introduction
4
introduction direct-acting
4
direct-acting antiviral
4
antiviral agents
4

Similar Publications

Background: Despite simplified hepatitis C virus (HCV) treatment algorithms, insurance-related barriers prevent same-day HCV treatment upon diagnosis in the US. We assessed how direct partnerships with a pharmacy team facilitated HCV treatment initiation among socially marginalized populations in a community setting.

Methods: The No One Waits (NOW) Study, a single-arm trial conducted between July 1, 2020, and October 31, 2021, in San Francisco, CA, targeted individuals experiencing homelessness, injecting drugs, and eligible for simplified HCV treatment.

View Article and Find Full Text PDF

Offering is not enough: an attempt to increase infectious diseases testing at a large county jail in Massachusetts.

Health Justice

March 2025

Department of Medicine, Division of Geographic Medicine and Infectious Disease, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA.

Background: Eliminating infectious diseases epidemics requires resources for testing, prevention, and treatment in jails. The 2022 Centers for Diseases Control and Prevention guidelines recommend offering hepatitis C virus (HCV), HIV, and STI testing at jail intake. Currently, the impact of offering testing at intake in jails has only been analyzed in the context of multi-modal strategies to increase testing.

View Article and Find Full Text PDF

Background: The development of effective direct-acting antiviral treatment (DAAT) for hepatitis C virus (HCV) has opened the possibility of using HCV+ donors. We aimed to assess the long-term feasibility of lung transplantation using organs from HCV+ donors.

Methods: We used the UNOS database to evaluate adult lung transplant recipients between 2000 and 2023.

View Article and Find Full Text PDF

Safety-net emergency departments (EDs) are a critical component of the US health care system, delivering emergency care for patients in need, including vulnerable populations. EDs provide unscheduled acute care for patients 24 hours a day, 7 days a week, regardless of a person's ability to pay. In addition, EDs have transformed beyond their traditional roles of providing emergency services and being the centers for regionalized trauma, cardiac, and stroke care, to also becoming stewards of public health by leading screening and treatment efforts for nonemergent conditions, such as HIV, hepatitis C, mental health, and opioid use disorder.

View Article and Find Full Text PDF

Background: Lipotoxicity is one of the causes for the progression of fatty liver in chronic hepatitis (CH) towards end-stage liver diseases. The role of miRNAs in the signalling pathways of lipid metabolism has been studied, but their direct targets in this pathway have not been identified yet. Here, we have characterized a downregulated miRNA in CH namely miR-451a, which has a direct impact on the lipid metabolism pathway.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!